Combining capture ELISA and in vivo MxA test to detect neutralizing antibodies to interferon-beta in a large cohort of multiple sclerosis patients

Objective: To investigate the use of a capture ELISA and an in vivo MxA assay to determine the occurrence of antibodies and biological responses in a large number of multiple sclerosis (MS) patients treated with interferon-beta. Background: Beta-interferons (IFN-beta) are widely used in the treatment of MS. A significant number of patients develop neutralizing antibodies (NAbs) to the drug, which may eventually interfere with treatment efficacy. However, therapy fails in a significant number of patients, who do not develop NAbs. Design/methods: More than 1500 MS patients on interferon-beta therapy were included…